Literature DB >> 15801904

Cardiovascular risk parameters in men with ankylosing spondylitis in comparison with non-inflammatory control subjects: relevance of systemic inflammation.

Hiren Divecha1, Naveed Sattar, Ann Rumley, Lynne Cherry, Gordon D O Lowe, Roger Sturrock.   

Abstract

Men with AS (ankylosing spondylitis) are at elevated risk for CHD (coronary heart disease) but information on risk factors is sparse. We compared a range of conventional and novel risk factors in men with AS in comparison with healthy controls and, in particular, determined the influence of systemic inflammation. Twenty-seven men with confirmed AS and 19 controls matched for age were recruited. None of the men was taking lipid-lowering therapy. Risk factors inclusive of plasma lipids, IL-6 (interleukin-6), CRP (C-reactive protein), vWF (von Willebrand factor), fibrin D-dimer, ICAM-1 (intercellular cell-adhesion molecule-1) and fibrinogen were measured, and blood pressure and BMI (body mass index) were determined by standard techniques. A high proportion (70%) of men with AS were smokers compared with 37% of controls (P = 0.024). The AS patients also had a higher BMI. In analyses adjusted for BMI and smoking, men with AS had significantly higher IL-6 and CRP (approx. 9- and 6-fold elevated respectively; P < 0.001), fibrinogen (P = 0.013) and vWF (P = 0.008). Total cholesterol and HDL-C (high-density lipoprotein cholesterol) were lower (P < 0.05 and P = 0.073 respectively) in AS and thus the ratio was not different. Pulse pressure was also significantly higher in AS (P = 0.007). Notably, adjustment for IL-6 and CRP levels rendered all case-control risk factor differences, except pulse pressure, non-significant. In accordance with this finding, IL-6 correlated positively (r = 0.74, P < 0.001) with fibrinogen, but negatively (r = -0.46, P = 0.016) with total cholesterol concentration. In conclusion, men with AS have perturbances in several CHD risk factors, which appear to be driven principally by systemic inflammatory mediators. Inflammation-driven atherogenesis potentially contributes to the excess CHD risk in AS.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15801904     DOI: 10.1042/CS20040326

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  33 in total

1.  Increased disease activity is associated with a deteriorated lipid profile in patients with ankylosing spondylitis.

Authors:  V P van Halm; J C van Denderen; M J L Peters; J W R Twisk; M van der Paardt; I E van der Horst-Bruinsma; R J van de Stadt; M H M T de Koning; B A C Dijkmans; M T Nurmohamed
Journal:  Ann Rheum Dis       Date:  2006-04-27       Impact factor: 19.103

2.  Differences in cardiovascular manifestations between ankylosing spondylitis patients with and without kyphosis.

Authors:  Jun Fu; Manyan Wu; Yan Liang; Kai Song; Ming Ni; Yonggang Zhang; Jiying Chen
Journal:  Clin Rheumatol       Date:  2016-06-07       Impact factor: 2.980

Review 3.  Atherosclerosis and endothelial dysfunction in patients with ankylosing spondylitis.

Authors:  V F Azevedo; R Pecoits-Filho
Journal:  Rheumatol Int       Date:  2010-03-27       Impact factor: 2.631

4.  High prevalence of metabolic syndrome in patients with ankylosing spondylitis.

Authors:  Domenico Malesci; Alferio Niglio; Gianna Angela Mennillo; Rosario Buono; Gabriele Valentini; Giovanni La Montagna
Journal:  Clin Rheumatol       Date:  2006-08-25       Impact factor: 2.980

5.  Atherogenic index of plasma: a useful marker for subclinical atherosclerosis in ankylosing spondylitis : AIP associate with cIMT in AS.

Authors:  Erkan Cure; Abdullah Icli; Ali Ugur Uslu; Davut Sakiz; Medine Cumhur Cure; Rabia Aydogan Baykara; Fatma Yavuz; Sevket Arslan; Adem Kucuk
Journal:  Clin Rheumatol       Date:  2018-02-12       Impact factor: 2.980

6.  Plasma homocysteine status in patients with ankylosing spondylitis.

Authors:  James Cheng-Chung Wei; Ming-Shiou Jan; Chen-Tung Yu; Yi-Chia Huang; Chi-Chiang Yang; Hsi-Kai Tsou; Hong-Shan Lee; Chang-Tei Chou; Gregory Tsay; Ming-Chih Chou
Journal:  Clin Rheumatol       Date:  2006-09-21       Impact factor: 2.980

7.  The relationship between plasma homocysteine level and different treatment modalities in patients with ankylosing spondylitis.

Authors:  Erhan Capkin; Murat Karkucak; Ayşe Akyüz; Ahmet Alver; Aysegul Kucukali Turkyilmaz; Elif Zengin
Journal:  Rheumatol Int       Date:  2011-06-05       Impact factor: 2.631

Review 8.  Cardiovascular risk in the rheumatic disease patient undergoing orthopedic surgery.

Authors:  Susan M Goodman; C Ronald Mackenzie
Journal:  Curr Rheumatol Rep       Date:  2013-09       Impact factor: 4.592

9.  Endothelial dysfunction in ankylosing spondylitis improves after tumor necrosis factor-alpha blockade.

Authors:  Ashit Syngle; Kanchan Vohra; Anjali Sharma; L Kaur
Journal:  Clin Rheumatol       Date:  2010-03-05       Impact factor: 2.980

10.  Serum homocysteine level in patients with ankylosing spondylitis.

Authors:  Bedriye Mermerci Başkan; Filiz Sivas; Lale Akbulut Aktekin; Yasemin Pekin Doğan; Kürşat Ozoran; Hatice Bodur
Journal:  Rheumatol Int       Date:  2009-03-15       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.